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Abstract
The limiting antigen (LAg)-avidity assay is a serologic assay used for cross-sectional HIV incidence testing. We
compared the results obtained with the LAg-avidity assay using dried blood spot (DBS) samples stored at room
temperature (18C–25C) or stored frozen at -80C with results obtained from matched plasma samples.
Matched DBS and plasma samples (306 paired samples) were collected in the HIV Prevention Trials Network
(HPTN) 068 trial in South Africa (2012–2014). The DBS were stored at room temperature before testing.
Matched DBS and plasma samples (100 paired samples) from the Consortium for the Evaluation and Perfor-
mance of HIV Incidence Assays (CEPHIA) were collected in 2016 and were stored at -80C. All DBS testing
was performed in 2017. Differences in normalized optical density (ODn) were compared between matched DBS
and plasma samples. For DBS samples stored at room temperature (HPTN 068), the average difference in ODn
values for plasma versus DBS was 1.49 (95% confidence intervals [CI]: 1.36–1.62). In contrast, when DBS
samples were stored at -80C (CEPHIA), the average difference in ODn values for plasma versus DBS was
-0.22 (95% CI: -0.32 to -0.13). DBS samples stored at room temperature should not be used for cross-sectional
HIV incidence testing with the LAg-avidity assay.
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Estimating population-level HIV incidence is im-portant for monitoring the HIV epidemic and under-
standing the reach and impact of community-level interventions
for HIV prevention.1,2 However, measuring HIV incidence
is challenging. Currently, the gold standard for measuring
HIV incidence is through longitudinal cohort studies, which
are expensive and associated with selection bias. A more
feasible approach for estimating HIV incidence is to use
biomarkers to analyze samples from a cross-sectional sur-
vey.3 The current algorithm used by the U.S. Centers for
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Disease Control and Prevention (CDC) includes the limiting
antigen (LAg)-avidity assay (cutoff: normalized optical density
[ODn] < 1.5) and HIV viral load (cutoff: >1,000 copies/mL).
Use of dried blood spots (DBS) may increase the feasi-
bility of cross-sectional incidence testing, particularly for
field research in resource-limited settings. Collection of DBS
is less invasive than collecting plasma, less time intensive
since limited processing is required, and can be easily per-
formed in low-resource settings. However, information on
the performance of the LAg-avidity assay using DBS is
limited. A previous study showed that the LAg-avidity assay
results obtained using plasma and DBS were highly corre-
lated when DBS were stored at -80C.4 However, little has
been documented on how alternate storage conditions affect
DBS results using antibody-based assays for HIV incidence
testing.5,6 In this study, we compared the results obtained
with the LAg-avidity assay, using DBS stored at room tem-
perature and DBS stored frozen at -80C. Samples were
obtained from two sources: the HIV Prevention Trials Network
(HPTN) 068 Study7 and the Consortium for the Evaluation
and Performance of HIV Incidence Assays (CEPHIA).4
The first sample set included 306 matched plasma and
DBS samples from 150 participants with known duration of
infection enrolled in HPTN 068. These samples were pre-
pared on Whatman 903 Protein Saver Cards. Samples were
collected per manufacturer’s protocol, initially allowed to air
dry overnight, and then moved to a sealed bag with desiccant.
The samples were collected in South Africa from young
women aged 13–20 years between 2012 and 2014. Plasma
samples were stored at -80C; DBS samples were stored at
room temperature in closed plastic bags with desiccant.8 The
second sample set included 100 matched plasma and DBS
samples from 100 participants who provided samples for
CEPHIA. DBS samples from CEPHIA were prepared on
FIG. 1. Comparison of limiting antigen (LAg)-avidity results of paired plasma and dried blood spot samples stored in
different conditions. Comparison of LAg-avidity assay results from paired plasma and dried blood spots samples. (A) The
distribution of paired plasma and DBS LAg-avidity ODn values where the DBS were stored at room temperature. (B) The
distribution of paired plasma and DBS LAg-avidity ODn values where the DBS were stored at -80C. (C) Bland–Altman plot
comparing the difference in plasma minus DBS LAg-avidity ODn results over the average of those values where the DBS
samples were stored at room temperature. (D) Bland–Altman plot comparing the difference in plasma minus DBS LAg-avidity
ODn results over the average of those values where the DBS samples were stored at -80C. DBS, dried blood spots; LAg-
avidity, limiting antigen avidity; ODn, normalized optical density. Color images available online at www.liebertpub.com/aid
Whatman 903 Protein Saver Cards at different testing sites;
75 samples were from a site in the United States and 25
samples were from two sites in Brazil. Plasma samples were
stored at -80C; DBS samples were initially stored at -20C
and later moved for long-term storage at -80C in closed
plastic bags with desiccant.
For testing, 6 mm punches were taken from each sample
using the BSD600 PLUS sample puncher (Microelectronic
Systems, Australia). The puncher dispenses the disk directly
into the designated well; after each sample, two 6 mm blank
punches were made to reduce the chance of contamination
between sample punches. Punches were eluted in 500 ll of
sample diluent provided with the Maxim HIV-1 LAg-Avidity
Incidence DBS EIA (Rockville, MD), overnight at 4C. All
DBS samples were tested in 2017.
We compared the LAg-avidity assay ODn values for
paired plasma and DBS specimens using descriptive statistics
and a two-sample paired signed-rank test for continuous re-
sults. In addition, differences between continuous results
were observed using Bland–Altman plots. Differences in
binary outcomes were determined using Fisher’s exact test.
p-Values <.05 were considered statistically significant. All
analyses were performed using STATA SE, version 14.2
(StataCorp, College Station, TX).
Among the matched plasma and DBS samples from HPTN
068, the ODn values were significantly lower for DBS stored
at 25C (median 1.11 [interquartile range (IQR): 0.62–1.74])
than for plasma stored at -80C (median 3.34 [IQR: 1.97–
4.00]; p < .001; Fig. 1A). Figure 1B shows the differences in
ODn values for plasma versus DBS using a Bland–Altman
plot. The average difference in ODn values for plasma versus
DBS was 1.49 (95% confidence intervals [CI]: 1.36–1.62).
Furthermore, as the average ODn for DBS and plasma in-
creased, there was an increase in the difference between the
ODn values for the two sample types.
In contrast, among the matched CEPHIA samples, the
ODn values were not significantly different for DBS stored at
-80C (median 3.67 [IQR: 1.80–4.00]) compared to plasma
stored at -80C (median, 3.68 [IQR: 1.10–4.00]; p < .09;
Fig. 1C). Figure 1D shows the difference between plasma and
DBS results as the average plasma ODn increased, using
Bland–Altman plots. The average difference in ODn values
for plasma versus DBS was -0.22 (95% CI: -0.32 to -0.13).
For these samples, minor differences in the range in ODn
values were observed. These slight differences are consistent
with the variance of the assay on replicate, and are unlikely to
impact studies using DBS estimate incidence or compare
interventions.
These findings suggest DBS used for testing with the LAg-
avidity assay should not be stored at room temperature. DBS
samples stored at room temperature had lower ODn values,
indicating a decrease in antibody avidity. Samples with low
antibody may more likely be misclassified as being from
individuals with recent HIV infection, leading to overesti-
mation of HIV incidence. For the HPTN 068 study samples,
there were 31 samples from individuals known to be infected
>1 year and a viral load >1,000 copies/mL. None of these
individuals were misclassified when using plasma (0/31),
whereas half the DBS samples were misclassified (17/31),
p < .01. In contrast, for the CEPHIA samples, there were 34
such samples and the same unique patient time point mis-
classified for both plasma and DBS.
A key limitation of this study is the lack of repeat testing of
DBS at various temperatures. Thus, additional studies are
needed to determine how the duration of DBS storage at room
temperature impacts LAg-avidity assay results. Future stud-
ies could include a time course experiment where the same
sample is stored and evaluated at -80C and then stored at
room temperature. Systematic testing in time intervals after
initiating the room temperature storage will determine the
length of time that DBS samples could be stored at room
temperature before LAg-avidity assay results start to decay.
Additional studies are also needed to determine whether re-
sults observed in this study are also observed with other sero-
logic incidence assays.9
Ultimately, we recommend storing DBS for HIV incidence
testing at -80C; this is consistent with guidelines from the
Criteria and Laboratory Standards Institute (CLSI), which
recommend storing DBS at -80C for other types of HIV
testing,10 including viral loads, an assay needed for the in-
terpretation of LAg and other testing algorithms.
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